ADVM
- Adverum Biotechnologies, Inc.
()
Overview
Company Summary
Adverum Biotechnologies, Inc. is a clinical-stage biotechnology company focused on developing gene therapies to treat serious ocular and rare diseases. The company leverages its expertise in gene therapy and ocular biology to design novel therapies that address the underlying causes of these diseases.
One of Adverum's main assets is its proprietary vector technology called the adeno-associated virus (AAV) platform. This platform allows them to deliver therapeutic genes to targeted cells in the body, particularly in the eye. By doing so, they aim to address genetic defects and restore the normal function of cells, ultimately improving patient outcomes.
Adverum has a versatile pipeline of product candidates, including a lead program called ADVM-022, which targets the treatment of wet age-related macular degeneration (AMD). Wet AMD is a leading cause of blindness in older adults, and currently available treatments require frequent injections into the eye. ADVM-022 offers the potential for a one-time administration of a gene therapy, which could reduce the burden on patients and improve compliance.
The company is also developing other gene therapies for the treatment of other ocular diseases, including diabetic retinopathy, retinitis pigmentosa, and other rare genetic retinal disorders. Adverum's approach aims to provide long-term benefits to patients, potentially improving their quality of life and reducing the need for ongoing treatments.
As a clinical-stage company, Adverum is actively involved in conducting clinical trials to evaluate the safety and efficacy of their therapeutic candidates. Their goal is to obtain regulatory approval and bring these gene therapies to market, providing much-needed treatment options for patients suffering from these debilitating diseases.